Parkman Healthcare Partners LLC Acquires Shares of 2,416,518 InspireMD, Inc. $NSPR

Parkman Healthcare Partners LLC bought a new stake in shares of InspireMD, Inc. (NYSE:NSPR) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 2,416,518 shares of the company’s stock, valued at approximately $1,692,000. Parkman Healthcare Partners LLC owned about 5.16% of InspireMD as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Renaissance Technologies LLC purchased a new position in InspireMD during the first quarter worth $29,000. XTX Topco Ltd purchased a new stake in shares of InspireMD in the fourth quarter valued at $30,000. Virtu Financial LLC bought a new stake in shares of InspireMD in the 4th quarter worth about $31,000. Creative Planning bought a new stake in shares of InspireMD in the 2nd quarter worth about $44,000. Finally, Legato Capital Management LLC purchased a new position in shares of InspireMD during the 4th quarter worth about $48,000. Hedge funds and other institutional investors own 44.78% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on NSPR shares. Lake Street Capital set a $4.00 price target on shares of InspireMD in a report on Monday, May 4th. Piper Sandler reissued an “overweight” rating and issued a $3.00 price objective (down from $4.00) on shares of InspireMD in a research note on Tuesday, May 5th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $4.50.

InspireMD Stock Down 3.3%

NSPR stock opened at $0.87 on Tuesday. The business’s fifty day simple moving average is $0.74 and its two-hundred day simple moving average is $1.16. InspireMD, Inc. has a twelve month low of $0.63 and a twelve month high of $2.56. The firm has a market cap of $40.44 million, a price-to-earnings ratio of -1.16 and a beta of 0.81.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.